MG-262 (Z-Leu-Leu-Leu-B(OH)2): Reversible, Cell-Permeable Proteasome Inhibitor for Precision Research

Executive Summary: MG-262 (Z-Leu-Leu-Leu-B(OH)2) is a boronic peptide derivative that acts as a potent, reversible, and cell-permeable proteasome inhibitor (IC₅₀ = 122 nM in vitro) [APExBIO]. It selectively targets the chymotryptic activity of the proteasome, a core mechanism in the ubiquitin-proteasome system governing protein degradation and cellular proteostasis [Nature Metabolism, 2025]. MG-262 induces cell cycle arrest and apoptosis through mitochondrial dysfunction and caspase pathway activation, and inhibits osteoclast differentiation in a dose-dependent manner [MG132.com]. The compound is highly soluble in DMSO (≥24.57 mg/mL) and ethanol (≥96.4 mg/mL), but insoluble in water; it must be stored at -20°C and used in freshly prepared solution. This article synthesizes current evidence and best practices to support rigorous experimental design with MG-262 in cancer, inflammatory, and neurodegenerative disease research.

Biological Rationale

The ubiquitin-proteasome system (UPS) is essential for the selective degradation of intracellular proteins, maintaining cellular homeostasis and regulating pathways such as the cell cycle, apoptosis, and stress response (Nature Metabolism, 2025). In skeletal muscle, proteasome-mediated degradation is upregulated during atrophy, aging, and catabolic states, contributing to muscle mass loss. Inhibition of the proteasome is a validated strategy for dissecting the role of protein turnover in cancer, inflammatory, and neurodegenerative disease models. MG-262's reversible, cell-permeable design enables precise temporal control of proteasome chymotryptic activity, supporting mechanistic studies of UPS-regulated signaling and protein turnover (MG132.com). This extends prior reviews by providing granular benchmarks for in vitro and in vivo use.

Mechanism of Action of MG-262 (Z-Leu-Leu-Leu-B(OH)2)

MG-262 is a synthetic boronic acid dipeptide that selectively and reversibly inhibits the chymotryptic activity of the 20S proteasome core particle. Its peptide backbone (Z-Leu-Leu-Leu) confers affinity for the proteasome’s S1 binding pocket, while the boronic acid moiety forms a covalent but reversible complex with the proteasome’s catalytic threonine residue. This interaction blocks peptide bond hydrolysis in the proteasome’s chymotrypsin-like site, reducing turnover of polyubiquitinated proteins. The inhibition is concentration-dependent, with a reported IC₅₀ of 122 nM (measured in a fluorogenic substrate assay at 37°C) [APExBIO]. MG-262 is cell-permeable, allowing intracellular delivery and proteasome inhibition in intact cells and tissues.

Upon proteasome inhibition, cells accumulate misfolded or regulatory proteins, triggering downstream effects such as stabilization of cell cycle inhibitors (p21, p27), retinoblastoma hypophosphorylation, and activation of apoptosis signaling pathways (caspase-3 cleavage, PARP cleavage). MG-262 can also induce mitochondrial membrane potential loss and modulate MAP kinase and c-Jun pathways, as demonstrated in fibroblast and immune cell models [ProteaseInhibitorCocktail.com].

Evidence & Benchmarks

• MG-262 inhibits the chymotryptic activity of purified 20S proteasome with an IC₅₀ of 122 nM (fluorogenic peptide substrate, 37°C, buffer pH 7.5) [APExBIO].
• MG-262 is insoluble in water but soluble in DMSO (≥24.57 mg/mL) and ethanol (≥96.4 mg/mL), supporting a range of in vitro concentration regimes [APExBIO].
• In human nasal mucosa and polyp fibroblasts, MG-262 reduces cell viability by inducing cell cycle arrest, increasing p21 and p27, and triggering apoptosis (24–72 h exposure, 10–1000 nM range) [Nature Metabolism, 2025; Fig. 1–3].
• MG-262 causes mitochondrial membrane depolarization and caspase-3 activation, with subsequent PARP cleavage, as verified in apoptosis assays (western blot, flow cytometry) [MG132.com].
• Intravenous administration of MG-262 in rodent models leads to significant reduction in proteasome activity in multiple organs (liver, spleen, muscle) within 1–3 hours post-injection (dose: 1 mg/kg) [Nature Metabolism, 2025].
• MG-262 inhibits osteoclast differentiation in vitro in a dose-dependent manner (3–100 nM, TRAP staining, 72 h) [Annexin-V-Biotin.com].

This article expands upon prior reviews such as MG-262: Reversible, Cell-Permeable Proteasome Inhibitor for Apoptosis Research by providing updated quantitative benchmarks and clarifying storage/solubility parameters critical for reproducibility.

Applications, Limits & Misconceptions

MG-262 is a versatile tool for dissecting the UPS in cell biology, oncology, immunology, and neurodegeneration. Specific applications include:

• Cell cycle arrest studies: Quantitative analysis of G1/S arrest and cyclin-dependent kinase inhibitor stabilization.
• Apoptosis research: Induction and measurement of caspase pathway activation, mitochondrial depolarization, and PARP cleavage.
• Osteoclast differentiation inhibition: Assessment of bone metabolism and inflammatory bone disease models.
• Cancer and inflammatory disease models: Characterization of proteasome dependency and resistance mechanisms in tumor and immune cells.
• Neurodegenerative disease research: Modeling of protein turnover defects and proteostasis in neuronal tissues.

For further reading, MG-262: Unraveling Proteasome Inhibitor Mechanisms provides deeper mechanistic context, while this article adds new evidence on in vivo performance and solution stability.

Common Pitfalls or Misconceptions

• MG-262 is not soluble in water; inappropriate vehicle selection can result in precipitation and loss of activity.
• Proteasome inhibition by MG-262 is reversible; prolonged or repeated dosing may be required for sustained inhibition.
• MG-262 does not inhibit lysosomal degradation pathways (e.g., macroautophagy, CMA); it is selective for the proteasome and not suitable for dissecting all protein degradation routes (Nature Metabolism, 2025).
• Due to instability in solution, MG-262 solutions must be prepared fresh immediately before use to avoid degradation and reduced potency.
• MG-262 is not a therapeutic drug; it is a research reagent and not approved for clinical use.

Workflow Integration & Parameters

For optimal results, MG-262 should be dissolved in DMSO or ethanol to the desired working concentration. Stock solutions should be stored at -20°C and protected from moisture. Fresh working solutions are recommended for each experiment due to compound instability in solution. In cell-based assays, typical working concentrations range from 10 nM to 1 μM, with exposure times from 2 to 72 hours depending on cell type and endpoint. Proteasome inhibition can be monitored using fluorogenic peptide substrates or western blot detection of polyubiquitinated proteins. In vivo, intravenous dosing (1 mg/kg) achieves systemic proteasome inhibition within 1–3 hours. Controls should include vehicle-only and positive/negative proteasome inhibitors for benchmarking. Detailed protocols and troubleshooting strategies are available from APExBIO and in the MG-262 (Z-Leu-Leu-Leu-B(OH)2) product page (SKU: A8179).

This article clarifies and extends the protocol guidance found in MG-262: Unlocking Proteasome Inhibition by specifying quantitative storage, solubility, and dosing benchmarks.

Conclusion & Outlook

MG-262 (Z-Leu-Leu-Leu-B(OH)2) from APExBIO is a rigorously characterized, reversible, cell-permeable proteasome inhibitor that enables precise interrogation of proteasome function in diverse biological systems. Its potency, selectivity, and compatibility with in vitro and in vivo models make it a cornerstone reagent for studies of cell cycle regulation, apoptosis, and disease modeling. Future applications include integration with genetic or omics approaches to map UPS-dependent pathways and to benchmark new inhibitors. Proper attention to solubility, storage, and experimental controls is essential for reproducible results. For product specifications, protocols, and ordering, consult the MG-262 (Z-Leu-Leu-Leu-B(OH)2) product page (SKU: A8179).